Tag Archives: Multiplexed Diagnostics Market

Multiplexed Diagnostics Market – Emerging Trends and New Technologies Research 2016 – 2024

The global multiplexed diagnostics market is highly competitive and dominated by the three players accounting for a combined share of 59.5% in 2015. These top companies are: Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies. Transparency Market Research finds that the leading players are constantly offering a diverse product portfolio, investing in acquiring advanced technologies, and expanding their regional presence to gain a competitive edge over others.

The market is otherwise fragmented with the presence of numerous small and mid-sized enterprises holding minor shares. Acquiring high-performing patented technologies, strengthening of distribution network, and intensifying manufacturing activities require substantial investment. This results in a high degree of competition, which poses significant entry barriers for new players. In order to consolidate their presence across regions, the large players are actively resorting to partnerships, mergers, and acquisitions.

This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

According to TMR’s estimation, the valuation of the global market for multiplexed diagnostics exceeded US$6.0 bn at the end of 2016. From 2016 to 2024, the market is anticipated to exhibit a consistent growth to attain US$26.36 bn by 2024; the global market, when measured in terms of revenue, is expected to expand at a 20.3% CAGR over the forecast period.

Innovative Multiplex Diagnostic Platform to Transform Cardiovascular Care

Geographically, the global multiplexed diagnostics market is segmented into Asia Pacific, North America, Latin America, the Middle East & Africa, and Europe. North America occupied a major market share in 2015. The regional market is anticipated to lead the market along the forecast period. The impressive growth is attributed to a wide prevalence of cardiovascular diseases, rising incidence of cancer in the U.S., and increasing geriatric population. The rapidly evolving healthcare services and innovations in healthcare IT in the U.S. have created ample opportunities for several players, which is expected to propel the regional market. Coupled with this, an enlarged scope of various reimbursements from both public as well as private players is expected to trigger the market growth.

On the basis of application, the multiplexed diagnostics market is segmented into cardiac diseases, oncology, autoimmune diseases, allergies, and infectious disease diagnostic. Of these, cardiac diseases, oncology, and infectious disease diagnostics are prominent market segments providing lucrative opportunities for numerous players to capitalize on. The cardiac disease diagnostics market is anticipated to grow at the highest rate due to wide prevalence of cardiovascular diseases, coupled with the design of high-throughput multiplex diagnostic equipment.

Automation in Multiplex PCR Systems Opens Promising Avenues for Disease Diagnosis

The global multiplexed diagnostics market is primarily driven by the soaring R&D investments by public as well as private players in the areas of genomics and personalized therapies. Constant advances in multiplex diagnostic technology have led to the application of targeted assay for detecting various pathogens for a wide spectrum of chronic and life-threatening diseases, such as neurological and cardiovascular disorders. Multiplexed real-time polymerase chain reaction (PCR) assays, as precision-based diagnostics, enable the concurrent detection of specific pathogens in a single experiment. Automation in multiplex PCR assay has resulted in reduced hands-on-time and elimination of error with high sensitivity and specificity. Along with this, the application of real-time automated multiplex PCR kits helps in rapid detection and significant cost-savings for laboratories, boosting its demand across a large number of diagnostic facilities.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719

However, the high cost of multiplexed diagnostics assay equipment, combined with lack of operational expertise, is likely to impede the growth of the global multiplexed diagnostics market. Nevertheless, continuous automation in assay technology and application of high-throughput multiplexed PCRs for the detection of a wide range of pathogens are expected to open up exciting opportunities for the leading players.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Multiplexed Diagnostics Market (Technology – Very High Density, High Density, Medium Density, Low Density, and Next Generation Sequencing Assays; Application – Infectious Disease Diagnostics, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, and Pregnancy & Fertility Testing; End Use – Academic Research Institutes, Hospitals, Pharmaceuticals Companies, Clinical Research Organizations, and Diagnostic Laboratories) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

Multiplexed Diagnostics Market grows with growth of private and public funding in the fields of genomics and personalized medicines

Global Multiplexed Diagnostics Market: Snapshot

The growth of private and public funding in the fields of genomics and personalized medicineis currently a high value driver for the global multiplexed diagnostics market. It is boosting the demand for advanced diagnostic technologies for precision-based diagnostics of life-threatening diseases. Current positive trends in the global multiplexed diagnostics market include the increasing rate of extensive research and development efforts being made to expand and diversify the existing applications in multiplexed diagnostics, the development in generic platforms, and a greater use of multiplexed diagnostics in academic and research organizations. However, the global multiplexed diagnostics market is being restrained by high costs pertaining to multiplexed diagnostics assay equipment and testing and an overall lack of skilled labor for handling the advanced equipment.

This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

The global multiplexed diagnostics market was valued at US$5.0 bn in 2015. It is projected to reach US$26.36 bn by the end of 2024 after expanding at a CAGR of 20% from 2016 to 2024.

North America’s Dominance in Global Multiplexed Diagnostics Market to Continue

The global Multiplexed diagnostics market is segmented on the basis of regions, into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2015, North America bagged for the leading share of the market in terms of value, owing to a rising prevalence of cardiac diseases and cancer in the region. North American players in the multiplexed diagnostics market also benefitted from the greater level of penetration of the national health care services. The region is expected to continue dominating the global multiplexed diagnostics market till 2024, a likelihood attributed to the region’s high percentage of the geriatric population, an advanced and structured healthcare industry, and a large scope of application of reimbursement policies from both public and private sources.

In Europe, the market for multiplexed diagnostics is also expected to grow at a substantial rate with the growing involvement of academic and research institutes from Germany and the U.K. North America and Europe are projected to be highly lucrative markets for players from the global multiplexed diagnostics market. Conversely, multiplexed diagnostics have not yet found solid foundations in Latin America, Asia Pacific, and the Middle East & Africa to grow on for now.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719

Infectious Disease Diagnostics in Full Swing

In terms of applications, the global multiplexed diagnostics market can be divided into autoimmune diseases, oncology, cardiac diseases, infectious disease diagnostic, and allergies. In 2015, a collective lead was attributed to the two segments of infectious disease diagnostics and oncology, due to an increase in the prevalence of infectious diseases along with a growing count of patients suffering from breast cancer, colorectal cancer, and prostate cancer. Oncology, cardiac diseases, and infectious disease diagnostics are expected to be highly beneficial segments for players from the global multiplexed diagnostics market. The segment for cardiac diseases is expected to expand at leading rate over the coming years due to the growing prevalence of various cardiovascular diseases. In terms of end users, the global multiplexed diagnostics market was led by academic research institutes in 2015. It is also expected to be the dominant end user in the market till 2024, owing to an increasing contribution of universities and cancer research centers and the research projects in the field of genetic engineering.

Till 2015, the leading players in the global multiplexed diagnostics market included Agilent Technologies, Bio-Rad Laboratories, Inc., BioMérieux SA, F. Hoffmann-La Roche Ltd., Illumina, Inc., Luminex Corporation, Hologic, Inc., Thermo Fisher Scientific, Inc., Siemens Healthineers, and Abbott Laboratories.

 

Multiplexed Diagnostics Market 2016 – 2024: Equipment Automation in Full Swing, Drives Demand

Global Multiplexed Diagnostics Market: Snapshot

The growth of private and public funding in the fields of genomics and personalized medicineis currently a high value driver for the global multiplexed diagnostics market. It is boosting the demand for advanced diagnostic technologies for precision-based diagnostics of life-threatening diseases. Current positive trends in the global multiplexed diagnostics market include the increasing rate of extensive research and development efforts being made to expand and diversify the existing applications in multiplexed diagnostics, the development in generic platforms, and a greater use of multiplexed diagnostics in academic and research organizations. However, the global multiplexed diagnostics market is being restrained by high costs pertaining to multiplexed diagnostics assay equipment and testing and an overall lack of skilled labor for handling the advanced equipment.

This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

The global multiplexed diagnostics market was valued at US$5.0 bn in 2015. It is projected to reach US$26.36 bn by the end of 2024 after expanding at a CAGR of 20% from 2016 to 2024.

North America’s Dominance in Global Multiplexed Diagnostics Market to Continue

The global Multiplexed diagnostics market is segmented on the basis of regions, into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2015, North America bagged for the leading share of the market in terms of value, owing to a rising prevalence of cardiac diseases and cancer in the region. North American players in the multiplexed diagnostics market also benefitted from the greater level of penetration of the national health care services. The region is expected to continue dominating the global multiplexed diagnostics market till 2024, a likelihood attributed to the region’s high percentage of the geriatric population, an advanced and structured healthcare industry, and a large scope of application of reimbursement policies from both public and private sources.

In Europe, the market for multiplexed diagnostics is also expected to grow at a substantial rate with the growing involvement of academic and research institutes from Germany and the U.K. North America and Europe are projected to be highly lucrative markets for players from the global multiplexed diagnostics market. Conversely, multiplexed diagnostics have not yet found solid foundations in Latin America, Asia Pacific, and the Middle East & Africa to grow on for now.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719

Infectious Disease Diagnostics in Full Swing

In terms of applications, the global multiplexed diagnostics market can be divided into autoimmune diseases, oncology, cardiac diseases, infectious disease diagnostic, and allergies. In 2015, a collective lead was attributed to the two segments of infectious disease diagnostics and oncology, due to an increase in the prevalence of infectious diseases along with a growing count of patients suffering from breast cancer, colorectal cancer, and prostate cancer. Oncology, cardiac diseases, and infectious disease diagnostics are expected to be highly beneficial segments for players from the global multiplexed diagnostics market. The segment for cardiac diseases is expected to expand at leading rate over the coming years due to the growing prevalence of various cardiovascular diseases. In terms of end users, the global multiplexed diagnostics market was led by academic research institutes in 2015. It is also expected to be the dominant end user in the market till 2024, owing to an increasing contribution of universities and cancer research centers and the research projects in the field of genetic engineering.

Till 2015, the leading players in the global multiplexed diagnostics market included Agilent Technologies, Bio-Rad Laboratories, Inc., BioMérieux SA, F. Hoffmann-La Roche Ltd., Illumina, Inc., Luminex Corporation, Hologic, Inc., Thermo Fisher Scientific, Inc., Siemens Healthineers, and Abbott Laboratories.

 

Multiplexed Diagnostics Market grows with growth of private and public funding in the fields of genomics and personalized medicines

 A handful of players dominated the otherwise fragmented global multiplexed diagnostics market in 2015. Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies were the leaders of this market for 2015, with a collective share of 59.5% in terms of value. The market is defined by the presence of these few leaders and then the presence of a large number of small-scale and medium-scale enterprises that hold minor shares. The leaders of the global multiplexed diagnostics market in 2015 all showed a diverse product portfolio, the possession of advanced tech, and a wide area of regional presence.

This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

In a research report recently published by Transparency Market Research, the global multiplexed diagnostics market is expected to witness a high degree of competition over the coming years. This fact is primarily concluded from the high volume of smaller players in the market that are eyed by the fewer, larger ones in terms of partnerships, mergers, and acquisitions. Although the volume of smaller players in the global multiplexed diagnostics market currently is very high, the scope for new entrants is much lower than expected, due to the need for acquiring patented technologies and the establishment of sizeable manufacturing facilities, both of which can eat up a large contingent of a company’s capital, leaving very little to spend on building feasible distribution networks. The global multiplexed diagnostics market is expected to be valued a little over US$6.0 bn by the end of 2016. After showing a consistently optimistic CAGR of 20.3% on its revenue from 2016 to 2024, the market is expected to reach US$26.36 bn by the end of 2024.

Equipment Automation in Full Swing, Drives Demand for Multiplexed Diagnostics

“Tech automation using multiplexed diagnostics has so far been a blessing for scientists trying to generate a larger volume of sample results at lower costs. This forms the primary driver for the global multiplexed diagnostics market today. Players in the market are involved in multiple aspects of the healthcare industry in a similar manner. For instance, the automation of PCR amplification can be done using multiplexed diagnostic technologies, and can help users lower the rate of user-intervention required and the cuts down the overall hands-on efforts needed to get the program to execute. At the same time, this equipment automation can also allow a higher throughput, save time in processing and considerably reduce manual labor required, consequently cutting down the chances for errors,” states a TMR analyst.

The global multiplexed diagnostics market also finds a significant growth rate from the high priority funding that the field of genomics is currently receiving. The research community for multiplexed diagnostics has been able to avail this funding storm.

Multiplexed Diagnostics Assay a Costly Affair for Many

Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719

Multiplexed diagnostics is still a new concept for the healthcare industry and as with many nascent stage markets, solutions and products from it can be unaffordable for several small-scale and medium-scale clients. Multiplexed diagnostics assay tests are relatively very expensive when compared to single-plex assays tests, especially in terms of the initial investment required for the equipment.

“Despite its high costs, players in the global multiplexed diagnostics market can expect a booming demand in research and development efforts on the current applications for multiplexed diagnostics, thus providing them with ample opportunities over the coming years,” adds the analyst.

The information presented in this review is based on a Transparency Market Research report, titled, “Multiplexed Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

 

Multiplexed Diagnostics Market will grows at a CAGR of 20% with increasing prevalence of cancer and infectious diseases

Global Multiplexed Diagnostics Market: Snapshot

The growth of private and public funding in the fields of genomics and personalized medicineis currently a high value driver for the global multiplexed diagnostics market. It is boosting the demand for advanced diagnostic technologies for precision-based diagnostics of life-threatening diseases. Current positive trends in the global multiplexed diagnostics market include the increasing rate of extensive research and development efforts being made to expand and diversify the existing applications in multiplexed diagnostics, the development in generic platforms, and a greater use of multiplexed diagnostics in academic and research organizations. However, the global multiplexed diagnostics market is being restrained by high costs pertaining to multiplexed diagnostics assay equipment and testing and an overall lack of skilled labor for handling the advanced equipment.

Read Full Report: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

The global multiplexed diagnostics market was valued at US$5.0 bn in 2015. It is projected to reach US$26.36 bn by the end of 2024 after expanding at a CAGR of 20% from 2016 to 2024.

North America’s Dominance in Global Multiplexed Diagnostics Market to Continue

The global Multiplexed diagnostics market is segmented on the basis of regions, into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2015, North America bagged for the leading share of the market in terms of value, owing to a rising prevalence of cardiac diseases and cancer in the region. North American players in the multiplexed diagnostics market also benefitted from the greater level of penetration of the national health care services. The region is expected to continue dominating the global multiplexed diagnostics market till 2024, a likelihood attributed to the region’s high percentage of the geriatric population, an advanced and structured healthcare industry, and a large scope of application of reimbursement policies from both public and private sources.

In Europe, the market for multiplexed diagnostics is also expected to grow at a substantial rate with the growing involvement of academic and research institutes from Germany and the U.K. North America and Europe are projected to be highly lucrative markets for players from the global multiplexed diagnostics market. Conversely, multiplexed diagnostics have not yet found solid foundations in Latin America, Asia Pacific, and the Middle East & Africa to grow on for now.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719

Infectious Disease Diagnostics in Full Swing

In terms of applications, the global multiplexed diagnostics market can be divided into autoimmune diseases, oncology, cardiac diseases, infectious disease diagnostic, and allergies. In 2015, a collective lead was attributed to the two segments of infectious disease diagnostics and oncology, due to an increase in the prevalence of infectious diseases along with a growing count of patients suffering from breast cancer, colorectal cancer, and prostate cancer. Oncology, cardiac diseases, and infectious disease diagnostics are expected to be highly beneficial segments for players from the global multiplexed diagnostics market. The segment for cardiac diseases is expected to expand at leading rate over the coming years due to the growing prevalence of various cardiovascular diseases. In terms of end users, the global multiplexed diagnostics market was led by academic research institutes in 2015. It is also expected to be the dominant end user in the market till 2024, owing to an increasing contribution of universities and cancer research centers and the research projects in the field of genetic engineering.

Till 2015, the leading players in the global multiplexed diagnostics market included Agilent Technologies, Bio-Rad Laboratories, Inc., BioMérieux SA, F. Hoffmann-La Roche Ltd., Illumina, Inc., Luminex Corporation, Hologic, Inc., Thermo Fisher Scientific, Inc., Siemens Healthineers, and Abbott Laboratories.